Continuing to reshape its business, Sanofi (NYSE:SNY) is in talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for €1.9B.
That’s after spending more than $16B to buy biotech company Ablynx and U.S. haemophilia specialist Bioverativ.
This week, Sanofi also sold some brands to Charterhouse Capital Partners’ Cooper-Vemedia drugs manufacturing arm for €158M.
